Melanoma oncologist at The Christie. Wellcome early career fellow at University of Manchester, The Francis Crick and UCL. Interested in tumour local and systemic immune changes, metastasis, ctdna and cancer evolution. Music, art, politics, hiking.
Becki Lee
Loading...
This was a small study and not powered to determine efficacy, but it provides a foundation for future ctDNA studies in melanoma and treatment sequencing approaches.
Thanks to funders, participating sites, and especially the patients involved.
4/5
Key finding #3: longitudinal ctDNA monitoring provided early signals of both treatment response and resistance, often before radiological changes were seen. 📈
Exciting conference alert!
sites.manchester.ac.uk/from-lab-to-...
Fantastic speakers including Chris Marine, Christian Blank
Melanoma evolution
Local microenvironment of melanoma
Melanoma-host interactions
Precision immunotherapy
Emerging therapeutics
Clinical trials and real-world data
Becki Lee
3/5
Key finding #2: ctDNA enabled personalised treatment.
Patients started targeted therapy and switched to immunotherapy after an 80% reduction in BRAF VAF in ctDNA. All patients reached this threshold, typically within 2–3 weeks. 💊
2/5
Key finding #1: rapid, real-time ctDNA testing is feasible.
Across multiple centres, ctDNA results could be processed and reported within 7 days, supporting treatment decisions in real clinical practice. 🧬
Pleased to share results from the CAcTUS Phase II trial of ctDNA-guided therapy in BRAF-mutant advanced melanoma are now published! 🌵🧬
CAcTUS is the first melanoma trial to adapt treatment based on ctDNA testing.
Read: www.nature.com/articles/s41...
Becki Lee
Becki Lee
Becki Lee
Becki Lee
Targeted therapy (with BRAK and MEK inhibitors) and immune checkpoint blockade have improved survival for patients with advanced BRAF-mutant cutaneous melanoma, however, the optimal scheduling for the...
www.deadlanguagesociety.com/p/how-far-ba...
I cannot speak as to the accuracy of the piece yet I found it a fascinating exercise @adamroberts.bsky.social @drlauravarnam.bsky.social
OpenSAFELY is open from today! Huge thanks to all who supported this vast collaboration: whole population GP data; in a productive platform; innovative privacy protections; unprecedented support from professions, privacy campaigners; &c
Now it's over to users!
www.bennett.ox.ac.uk/blog/2026/02...
👉...cutting-edge science, clinical insights & discussions re: real-world implementation of TIL therapy.
Featuring keynote speakers:
Inge Marie Svane 🇩🇰 & Sebastian Klobuch 🇳🇱.
@sklobuch.bsky.social
@debrajosephs.bsky.social
@turajliclab.bsky.social
@beckilee.bsky.social
🩺 Fantastic opportunity for #YoungOncologists: ICF-ESMO programme for an 8-week observership.
We've excellent opportunities here in Manchester & would be happy to support (✉️: [email protected]).
@christieinstitute.bsky.social
@myesmo.bsky.social
📥 For more info (due 25 Jan 2026) 👇
